The second-generation IL-7 drug, NT-I7 (efineptakin alfa), uses a hybrid human IgG/IgD Fc domain for half-life extension (T1/2=60.8–139.7 hr), which significantly improves its anti-tumor activities. Here, IL7 is linked to neoplasm.